Video Interview: Prothena Tackles Diseases Of Protein Accumulation

Prothena President and CEO Dr. Dale Schenk briefs Mike Ward, global director of content of Informa's pharma insights portfolio, on the progress the company has made since it spun out of Elan Corp at the end of 2012. The Irish company has three antibody programs focusing on diseases associated with protein accumulation in the clinic. The lead program is NEOD001, which is a monoclonal antibody targeting the amyloid that accumulates in light chain amyloidosis. Dr. Schenk reveals that he expects to report results from the Phase IIb PRONTO trial at the end of 2017, early 2018, while the results of the pivotal Phase III VITAL study will come after that. In collaboration with Roche, the company is developing a monoclonal antibody, PRX002, that targets alpha-synuclein, a protein that has a fundamental role in the progression of Parkinson's disease and other conditions. Dr. Schenk reveals that the company has already completed one Phase I study with the molecule and is expecting to report the results of a much larger Phase I trial by the end of 2016. The third program is a monoclonal antibody, PRX003, that selectively blocks MCAM-mediated cell adhesion, which is in Phase I trials and is being developed as a treatment for psoriasis and other inflammatory conditions.

Prothena President and CEO Dr. Dale Schenk briefs Mike Ward, global director of content of Informa's pharma insights portfolio, on the progress the company has made since it spun out of Elan Corp at the end of 2012. The Irish company has three antibody programs focusing on diseases associated with protein accumulation in the clinic. The lead program is NEOD001, which is a monoclonal antibody targeting the amyloid that accumulates in light chain amyloidosis. Dr. Schenk reveals that he expects to report results from the Phase IIb PRONTO trial at the end of 2017, early 2018, while the results of the pivotal Phase III VITAL study will come after that. In collaboration with Roche, the company is developing a monoclonal antibody, PRX002, that targets alpha-synuclein, a protein that has a fundamental role in the progression of Parkinson's disease and other conditions. Dr. Schenk reveals that the company has already completed one Phase I study with the molecule and is expecting to report the results of a much larger Phase I trial by the end of 2016. The third program is a monoclonal antibody, PRX003, that selectively blocks MCAM-mediated cell adhesion, which is in Phase I trials and is being developed as a treatment for psoriasis and other inflammatory conditions.

This interview took place during EBD Group's Biotech Showcase in San Francisco, Jan. 11-13, 2016. Further panel discussions and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Dermatological

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By 

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

What Incyte Investors Expect From New CEO Bill Meury

 

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Nektar Bounces Back As Eczema Drug Rezpeg Heads For Phase III

 
• By 

Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.

More from Therapy Areas

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.